Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416249 | 0.78 | MAPK8 (0.48) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL27103142 | 0.77 | TYRO3 (0.50) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL1983844 | 0.77 | ALDH1A1 (0.43) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL7548296 | 0.77 | PDE3B (0.39) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL3745415 | 0.77 | MAPK8 (0.41) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL4129449 | 0.77 | DYRK1A (0.41) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL22652309 | 0.77 | MAPK8 (0.39) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL21455110 | 0.77 | MAPK8 (0.39) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL22652124 | 0.77 | MAPK8 (0.44) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL660796 | 0.77 | MEN1 (0.40) | PDE3BPDE3AMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | claimed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | claimed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | claimed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-115605479-B | Pyridopyrimidine derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115605479-A | Pyridoneopyrimidine derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3024456-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | PDE3B 782/4885PDE3A 1279/4885MAPK8 885/4885 |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PDE3B 760/4885PDE3A 1023/4885MAPK8 437/4885 |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PDE3B 760/4885PDE3A 1023/4885MAPK8 437/4885 |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | DPYD, TYMP, TYMS | PDE3B 408/4885PDE3A 431/4885MAPK8 2507/4885 |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, SOS1, HINT1 | PDE3B 2677/4885PDE3A 2350/4885MAPK8 243/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | PDE3B 3205/4885PDE3A 3212/4885MAPK8 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.